NCT07149246 The Effect of a 6-month Dietitian-tailored Nutrition Intervention to Patients With Critical Illness (DETAIL)
| NCT ID | NCT07149246 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of North Norway |
| Condition | ICU Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-09-01 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research project aims to study the effect of optimal and individualised nutrition to patients with critical illness during the intensive care unit (ICU) and hospital admission, and until six months after admission. The investigators want to describe and compare the usual care with a dietitian-tailored nutrition care. The hypothesis is that dietitian-tailored nutrition care will result in a higher mean energy intake compared to usual care.
Eligibility Criteria
Inclusion Criteria: Patients in intensive care who gives an informed consent and meet all of the following will be eligible: 1. Admitted to the intensive care unit for \>48 hours. 2. At least 18 years of age 3. Have one or more organ system failure (respiratory,cardiovascular or renal) related to their acute illness defined as: a. PaO2/FiO2≤300 mm Hg) b. Currently on one or more continuous inotrope/vasopressor infusion which were started at least 4 hours ago at a minimum dose of: i. Norepinephrine≥0.1 mcg/kg/min ii. Epinephrine≥0.1 mcg/kg/min iii. Any dose of vasopressin iv. Milrinone\>0.1 mcg/kg/min) c. Renal dysfunction defined as: i. Serum creatinine 2.0-2.9 times baseline or ii. Urine output 0.5 mL/kg/hour for ≥12 hours or iii. Currently receiving renal replacement therapy) d. Currently has an intracranial pressure monitor or ventricular drain in situ 4. Permanent living address in Norway Exclusion Criteria: Patients will be excluded if: 1. Death is imminent in the next 96 hours or there is a current treatment limitation in place or the patient is unlikely to survive to 180 days due to underlying/chronic illness 2. Dialysis dependent chronic renal failure 3. Suspected or known pregnancy 4. Wheelchair user 5. Cognitive impairment in which intervention is considered not appropriate 6. Eating disorders -
Contact & Investigator
Anders Benjamin Kildal, MD, PHD
PRINCIPAL INVESTIGATOR
University Hospital of North Norway
Frequently Asked Questions
Who can join the NCT07149246 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ICU Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07149246 currently recruiting?
Yes, NCT07149246 is actively recruiting participants. Contact the research team at anders.benjamin.kildal@unn.no for enrollment information.
Where is the NCT07149246 trial being conducted?
This trial is being conducted at Tromsø, Norway.
Who is sponsoring the NCT07149246 clinical trial?
NCT07149246 is sponsored by University Hospital of North Norway. The principal investigator is Anders Benjamin Kildal, MD, PHD at University Hospital of North Norway. The trial plans to enroll 300 participants.